clinical trial · NCT07595913
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd·phase3·not yet recruiting·n = 240
Neuroendocrine CarcinomaZG0065-fluorouracil, Calcium folinate and Irinotecan
brief summary
This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine carcinoma who have received prior systemic therapy.
started
Jul 1, 2026
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
May 19, 2026
official title
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol